A Search Service for Abbreviation / Long Form

■ Abbreviation / Long Form : SMM / smoldering myeloma

[Related PubMed/MEDLINE]
Total Number of Papers: 35
[Entries Per Page]
 per page
Page Control
Page: of
Abbreviation:   SMM  (>> Co-occurring Abbreviation)
Long Form:   smoldering myeloma
 Abbreviation Variation
 Long Form Variation
 Pair(Abbreviation/Long Form) Variation
No. Year Title Co-occurring Abbreviation
2022 Genome-wide profiling of 5-hydroxymethylcytosines in circulating cell-free DNA reveals population-specific pathways in the development of multiple myeloma. 5hmC, AA, cfDNA, EA, MGUS, MM
2021 Clonal Evolution of Multiple Myeloma-Clinical and Diagnostic Implications. MGUS, MM
2021 Laboratory Mice - A Driving Force in Immunopathology and Immunotherapy Studies of Human Multiple Myeloma. BM, GEMMs, MGUS, MM, PCTs
2021 Quantitative, Dynamic 18F-FDG PET/CT in Monitoring of Smoldering Myeloma: A Case Report. MM, PET/CT
2021 Single-cell RNA sequencing reveals compromised immune microenvironment in precursor stages of multiple myeloma. MM
2021 Smoldering multiple myeloma: evolving diagnostic criteria and treatment strategies. ---
2021 The benefits of early intervention using lenalidomide for high-risk smoldering multiple myeloma: emerging data and its promising clinical impact. MGUS
2021 The molecular make up of smoldering myeloma highlights the evolutionary pathways leading to multiple myeloma. MM
2021 Whole-genome sequencing reveals progressive versus stable myeloma precursor conditions as two distinct entities. MGUS, MM, WGS
10  2020 Extracellular Vesicle microRNAs Contribute to the Osteogenic Inhibition of Mesenchymal Stem Cells in Multiple Myeloma. ALPL, BM, EVs, hMSCs, MM, OBs
11  2020 How we manage smoldering multiple myeloma. ---
12  2020 Light Chain Predominant Intact Immunoglobulin Monoclonal Gammopathy Disorders: Shorter Survival in Light Chain Predominant Multiple Myelomas. Ig, LCs, MGUS, MMs
13  2020 Practical approach to the management of smoldering myeloma. ---
14  2019 Bone Marrow CX3CL1/Fractalkine is a New Player of the Pro-Angiogenic Microenvironment in Multiple Myeloma Patients. ADAM10, ADAM17, BM, CX3CL1, CX3CR1, ECs, MGUS, MM, TNF-alpha
15  2019 Impact of prior diagnosis of monoclonal gammopathy on outcomes in newly diagnosed multiple myeloma. MGs, MGUS, MM, OS, SPC
16  2019 Kidney transplantation for active multiple myeloma or smoldering myeloma: a case-control study. ESRD, KT, MM
17  2018 Monoclonal gammopathies of unknown significance and smoldering myeloma: Assessment and management of the elderly patients. IMGW, MGUS
18  2018 Pseudohyperphosphatemia in a patient with incidentally identified progression of smoldering myeloma. MM
19  2017 Expression of the IL-6 receptor alpha-chain (CD126) in normal and abnormal plasma cells in monoclonal gammopathy of undetermined significance and smoldering myeloma. aPCs, MGUS, MM, nPCs
20  2016 Increased circulating VCAM-1 correlates with advanced disease and poor survival in patients with multiple myeloma: reduction by post-bortezomib and lenalidomide treatment. ICAM-1, MGUS, MM, NDMM, OS, VCAM-1
21  2016 MGUS to myeloma: a mysterious gammopathy of underexplored significance. MGUS, MM
22  2016 Monoclonal gammopathy of undetermined significance (MGUS) and smoldering myeloma (SMM): a practical guide to management. MGUS, MM
23  2016 Polyclonal Immunoglobulin G N-Glycosylation in the Pathogenesis of Plasma Cell Disorders. CR, IgG, MGUS, MM
24  2016 Prognostic Impact of Serum Heavy/Light Chain Pairs in Patients With Monoclonal Gammopathy of Undetermined Significance and Smoldering Myeloma: Long-Term Results From a Single Institution. HLC, MGUS
25  2015 Stabilisation of Laryngeal AL Amyloidosis with Long Term Curcumin Therapy. AL, MGUS, MM, PCDs
26  2014 Altered cytokine and chemokine profiles in multiple myeloma and its precursor disease. BM, ELISA, MM, PB
27  2014 Immunoglobulin-free light chain monomer-dimer patterns help to distinguish malignant from premalignant monoclonal gammopathies: a pilot study. AL, FLC, MGUS, MM
28  2013 Angiogenic cytokines profile in smoldering multiple myeloma: no difference compared to MGUS but altered compared to symptomatic myeloma. Ang-1, Ang-2, MGUS, MM, VEGF
29  2013 Intraclonal heterogeneity is a critical early event in the development of myeloma and precedes the development of clinical symptoms. HR, MGUS, MM, PCL
30  2011 Competition between clonal plasma cells and normal cells for potentially overlapping bone marrow niches is associated with a progressively altered cellular distribution in MGUS vs myeloma. BM, HA, HSC, MGUS, MM, PB, PC, SDF-1
31  2011 Development of early treatment strategies for high-risk myeloma precursor disease in the future. MGUS
32  2011 Myelomagenesis: capturing early microenvironment changes. MGUS, MM, WHO
33  2007 Overexpression and involvement in migration by the metastasis-associated phosphatase PRL-3 in human myeloma cells. BM, MGUS, MM, PCs
34  2003 Frequent occurrence of CCND1 deregulation in patients with early stages of plasma cell dyscrasia. DC-FISH, IgH, MGUS, MM
35  1989 Serum levels of interleukin 6, a potent myeloma cell growth factor, as a reflect of disease severity in plasma cell dyscrasias. MGUS, MM, PCL